Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies.
Med Res Rev
; 44(5): 2078-2111, 2024 09.
Article
en En
| MEDLINE
| ID: mdl-38530106
ABSTRACT
As the world population ages, there will be an increasing need for effective therapies for aging-associated neurodegenerative disorders, which remain untreatable. Dementia due to Alzheimer's disease (AD) is one of the leading neurological diseases in the aging population. Current therapeutic approaches to treat this disorder are solely symptomatic, making the need for new molecular entities acting on the causes of the disease extremely urgent. One of the potential solutions is to use compounds that are already in the market. The structures have known pharmacokinetics, pharmacodynamics, toxicity profiles, and patient data available in several countries. Several drugs have been used successfully to treat diseases different from their original purposes, such as autoimmunity and peripheral inflammation. Herein, we divulge the repurposing of drugs in the area of neurodegenerative diseases, focusing on the therapeutic potential of antineoplastics to treat dementia due to AD and dementia. We briefly touch upon the shared pathological mechanism between AD and cancer and drug repurposing strategies, with a focus on artificial intelligence. Next, we bring out the current status of research on the development of drugs, provide supporting evidence from retrospective, clinical, and preclinical studies on antineoplastic use, and bring in new areas, such as repurposing drugs for the prion-like spreading of pathologies in treating AD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Demencia
/
Reposicionamiento de Medicamentos
/
Enfermedad de Alzheimer
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Med Res Rev
Año:
2024
Tipo del documento:
Article
País de afiliación:
República Checa
Pais de publicación:
Estados Unidos